Miconazole warnings and precautions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
===Hypersensitivity=== | ===Hypersensitivity=== | ||
Allergic reactions, including [[anaphylactic]] reactions and [[hypersensitivity]], have been reported with the administration of miconazole products, including | Allergic reactions, including [[anaphylactic]] reactions and [[hypersensitivity]], have been reported with the administration of miconazole products, including ORAVIG®. | ||
Discontinue | Discontinue ORAVIG® '''immediately''' at the first sign of [[hypersensitivity]]. | ||
There is '''no information''' regarding '''cross-hypersensitivity''' between miconazole and other azole antifungal agents. | There is '''no information''' regarding '''cross-hypersensitivity''' between miconazole and other azole antifungal agents. | ||
Latest revision as of 09:00, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Warnings and Precautions
Hypersensitivity
Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including ORAVIG®.
Discontinue ORAVIG® immediately at the first sign of hypersensitivity.
There is no information regarding cross-hypersensitivity between miconazole and other azole antifungal agents.
Monitor patients with a history of hypersensitivity to azoles.[1]
References
Adapted from the FDA Package Insert.